US20040138125A1 - Composition and method to prevent and treat brain and spinal cord injuries - Google Patents
Composition and method to prevent and treat brain and spinal cord injuries Download PDFInfo
- Publication number
- US20040138125A1 US20040138125A1 US10/744,114 US74411403A US2004138125A1 US 20040138125 A1 US20040138125 A1 US 20040138125A1 US 74411403 A US74411403 A US 74411403A US 2004138125 A1 US2004138125 A1 US 2004138125A1
- Authority
- US
- United States
- Prior art keywords
- mammal
- nervous system
- central nervous
- protecting
- neuroprotective composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 238000000034 method Methods 0.000 title claims abstract description 38
- 210000004556 brain Anatomy 0.000 title description 33
- 208000020431 spinal cord injury Diseases 0.000 title description 12
- 208000029028 brain injury Diseases 0.000 title description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims abstract description 112
- 210000003169 central nervous system Anatomy 0.000 claims abstract description 52
- 210000001519 tissue Anatomy 0.000 claims abstract description 44
- 210000002330 subarachnoid space Anatomy 0.000 claims abstract description 18
- 230000003204 osmotic effect Effects 0.000 claims abstract description 16
- 239000002357 osmotic agent Substances 0.000 claims description 34
- 230000000324 neuroprotective effect Effects 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 21
- 239000013078 crystal Substances 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000005557 antagonist Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 230000017531 blood circulation Effects 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims description 5
- 108010039918 Polylysine Proteins 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 239000003527 fibrinolytic agent Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229920000656 polylysine Polymers 0.000 claims description 5
- 229960000103 thrombolytic agent Drugs 0.000 claims description 5
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000480 calcium channel blocker Substances 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- 239000003148 4 aminobutyric acid receptor blocking agent Substances 0.000 claims description 2
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 claims description 2
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 108091006146 Channels Proteins 0.000 claims description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 claims description 2
- 229940123457 Free radical scavenger Drugs 0.000 claims description 2
- 229940098788 GABA receptor antagonist Drugs 0.000 claims description 2
- 229940122459 Glutamate antagonist Drugs 0.000 claims description 2
- 239000004471 Glycine Substances 0.000 claims description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 2
- HQRSUIDICNOLPX-UHFFFAOYSA-M Mersalyl acid Chemical group O[Hg]CC(OC)CNC(=O)C1=CC=CC=C1OCC(O)=O HQRSUIDICNOLPX-UHFFFAOYSA-M 0.000 claims description 2
- 229940123134 Nitric oxide inhibitor Drugs 0.000 claims description 2
- 229940127315 Potassium Channel Openers Drugs 0.000 claims description 2
- 102000013275 Somatomedins Human genes 0.000 claims description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 claims description 2
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims description 2
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 claims description 2
- 229960000224 mersalyl Drugs 0.000 claims description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 claims description 2
- 229920000768 polyamine Polymers 0.000 claims description 2
- 239000003450 potassium channel blocker Substances 0.000 claims description 2
- 239000003909 protein kinase inhibitor Substances 0.000 claims description 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 claims description 2
- 239000002516 radical scavenger Substances 0.000 claims description 2
- 239000000952 serotonin receptor agonist Substances 0.000 claims description 2
- 239000003195 sodium channel blocking agent Substances 0.000 claims description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 23
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000014674 injury Diseases 0.000 abstract description 25
- 230000006378 damage Effects 0.000 abstract description 23
- 208000027418 Wounds and injury Diseases 0.000 abstract description 20
- 229910001868 water Inorganic materials 0.000 description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 210000000278 spinal cord Anatomy 0.000 description 21
- 241000283973 Oryctolagus cuniculus Species 0.000 description 18
- 208000028867 ischemia Diseases 0.000 description 14
- 206010030113 Oedema Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 206010048962 Brain oedema Diseases 0.000 description 10
- 208000006752 brain edema Diseases 0.000 description 10
- 239000012530 fluid Substances 0.000 description 9
- 230000033001 locomotion Effects 0.000 description 9
- 102000009027 Albumins Human genes 0.000 description 8
- 108010088751 Albumins Proteins 0.000 description 8
- 208000006011 Stroke Diseases 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 206010058558 Hypoperfusion Diseases 0.000 description 7
- 210000003703 cisterna magna Anatomy 0.000 description 7
- 210000003414 extremity Anatomy 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 210000003141 lower extremity Anatomy 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 201000006474 Brain Ischemia Diseases 0.000 description 6
- 230000002497 edematous effect Effects 0.000 description 6
- 210000003625 skull Anatomy 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 230000002159 abnormal effect Effects 0.000 description 5
- -1 and Substances 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004204 blood vessel Anatomy 0.000 description 5
- 238000007917 intracranial administration Methods 0.000 description 5
- 230000001926 lymphatic effect Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 210000004785 virchow-robin space Anatomy 0.000 description 5
- 208000007204 Brain death Diseases 0.000 description 4
- 206010069729 Collateral circulation Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- MEXAGTSTSPYCEP-NUBCRITNSA-N (2r)-2,6-diaminohexanoic acid;hydrobromide Chemical compound Br.NCCCC[C@@H](N)C(O)=O MEXAGTSTSPYCEP-NUBCRITNSA-N 0.000 description 3
- 241001631457 Cannula Species 0.000 description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 description 3
- 208000010496 Heart Arrest Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 206010028851 Necrosis Diseases 0.000 description 3
- 206010033892 Paraplegia Diseases 0.000 description 3
- 208000032930 Spastic paraplegia Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 210000005056 cell body Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004904 fingernail bed Anatomy 0.000 description 3
- 230000002706 hydrostatic effect Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 208000037906 ischaemic injury Diseases 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 230000007971 neurological deficit Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241001269524 Dura Species 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- LPMRCCNDNGONCD-RITPCOANSA-N Selfotel Chemical compound OC(=O)[C@@H]1C[C@H](CP(O)(O)=O)CCN1 LPMRCCNDNGONCD-RITPCOANSA-N 0.000 description 2
- 208000036982 Spinal cord ischaemia Diseases 0.000 description 2
- 241000287181 Sturnus vulgaris Species 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000006736 behavioral deficit Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- XLZOVRYBVCMCGL-BPNVQINPSA-L disodium;4-[(z)-[tert-butyl(oxido)azaniumylidene]methyl]benzene-1,3-disulfonate Chemical compound [Na+].[Na+].CC(C)(C)[N+](\[O-])=C\C1=CC=C(S([O-])(=O)=O)C=C1S([O-])(=O)=O XLZOVRYBVCMCGL-BPNVQINPSA-L 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000003722 extracellular fluid Anatomy 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- WZMQMKNCWDCCMT-UHFFFAOYSA-N fanapanel Chemical compound FC(F)(F)C=1C=C2NC(=O)C(=O)N(CP(O)(=O)O)C2=CC=1N1CCOCC1 WZMQMKNCWDCCMT-UHFFFAOYSA-N 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000000266 injurious effect Effects 0.000 description 2
- OZFSWVOEXHGDES-INIZCTEOSA-N lubeluzole Chemical compound C([C@@H](O)CN1CCC(CC1)N(C)C=1SC2=CC=CC=C2N=1)OC1=CC=C(F)C(F)=C1 OZFSWVOEXHGDES-INIZCTEOSA-N 0.000 description 2
- 229950009851 lubeluzole Drugs 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000007659 motor function Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000004090 neuroprotective agent Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 108010055896 polyornithine Proteins 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 210000002254 renal artery Anatomy 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 230000037152 sensory function Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- KRKRAOXTGDJWNI-DMTCNVIQSA-N (2s,4r)-2-amino-4-methylpentanedioic acid Chemical compound OC(=O)[C@H](C)C[C@H](N)C(O)=O KRKRAOXTGDJWNI-DMTCNVIQSA-N 0.000 description 1
- ULYONBAOIMCNEH-HNNXBMFYSA-N (3s)-3-(5-chloro-2-methoxyphenyl)-3-fluoro-6-(trifluoromethyl)-1h-indol-2-one Chemical compound COC1=CC=C(Cl)C=C1[C@@]1(F)C2=CC=C(C(F)(F)F)C=C2NC1=O ULYONBAOIMCNEH-HNNXBMFYSA-N 0.000 description 1
- JFLUCCKXAYBETQ-VIFPVBQESA-N (4s)-4-(2-methylpropylamino)-7,7-dioxo-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide Chemical compound CC(C)CN[C@H]1CCS(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 JFLUCCKXAYBETQ-VIFPVBQESA-N 0.000 description 1
- WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- CKAKVKWRMCAYJD-UHFFFAOYSA-N 1-(3-ethylphenyl)-1-methyl-2-naphthalen-1-ylguanidine;hydrochloride Chemical compound Cl.CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 CKAKVKWRMCAYJD-UHFFFAOYSA-N 0.000 description 1
- GGUSQTSTQSHJAH-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-(4-fluorobenzyl)piperidin-1-yl]ethanol Chemical compound C=1C=C(Cl)C=CC=1C(O)CN(CC1)CCC1CC1=CC=C(F)C=C1 GGUSQTSTQSHJAH-UHFFFAOYSA-N 0.000 description 1
- UQNAFPHGVPVTAL-UHFFFAOYSA-N 2,3-Dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline Chemical compound N1C(=O)C(=O)NC2=C1C=C([N+]([O-])=O)C1=C2C=CC=C1S(=O)(=O)N UQNAFPHGVPVTAL-UHFFFAOYSA-N 0.000 description 1
- AYMCBYVXAOYZTC-UHFFFAOYSA-O 2-(1-ethylpyridin-1-ium-2-yl)-21,22-dihydroporphyrin Chemical compound CC[N+]1=CC=CC=C1C1=CC2=CC([N]3)=CC=C3C=C(C=C3)NC3=CC([N]3)=CC=C3C=C1N2 AYMCBYVXAOYZTC-UHFFFAOYSA-O 0.000 description 1
- FTGBVHPWUIHWRH-UHFFFAOYSA-N 2-[2-[2-[2-[carboxymethyl-[2-(2-octoxyethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(2-octoxyethoxy)-2-oxoethyl]anilino]acetic acid Chemical compound CCCCCCCCOCCOC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(=O)OCCOCCCCCCCC FTGBVHPWUIHWRH-UHFFFAOYSA-N 0.000 description 1
- YSGASDXSLKIKOD-UHFFFAOYSA-N 2-amino-N-(1,2-diphenylpropan-2-yl)acetamide Chemical compound C=1C=CC=CC=1C(C)(NC(=O)CN)CC1=CC=CC=C1 YSGASDXSLKIKOD-UHFFFAOYSA-N 0.000 description 1
- MGNMVYXIKDNAKK-UHFFFAOYSA-N 3,3-bis(3-fluorophenyl)-n-methylpropan-1-amine;hydron;chloride Chemical compound Cl.C=1C=CC(F)=CC=1C(CCNC)C1=CC=CC(F)=C1 MGNMVYXIKDNAKK-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 1
- 208000035657 Abasia Diseases 0.000 description 1
- 101100041235 Bacillus subtilis (strain 168) rtpA gene Proteins 0.000 description 1
- 102100037597 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- PCLITLDOTJTVDJ-UHFFFAOYSA-N Chlormethiazole Chemical compound CC=1N=CSC=1CCCl PCLITLDOTJTVDJ-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010011985 Decubitus ulcer Diseases 0.000 description 1
- 239000012848 Dextrorphan Substances 0.000 description 1
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- LFBZZHVSGAHQPP-UHFFFAOYSA-N GYKI 52466 Chemical compound C12=CC=3OCOC=3C=C2CC(C)=NN=C1C1=CC=C(N)C=C1 LFBZZHVSGAHQPP-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 206010037538 Pupils unequal Diseases 0.000 description 1
- PDOCBJADCWMDGL-UHFFFAOYSA-N Sipatrigine Chemical compound C1CN(C)CCN1C1=NC=C(C=2C(=C(Cl)C=C(Cl)C=2)Cl)C(N)=N1 PDOCBJADCWMDGL-UHFFFAOYSA-N 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000010513 Stupor Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010039185 Tenecteplase Proteins 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 235000021120 animal protein Nutrition 0.000 description 1
- 208000001239 anisocoria Diseases 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000007474 aortic aneurysm Diseases 0.000 description 1
- 208000008784 apnea Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- BFNCJMURTMZBTE-UHFFFAOYSA-N aptiganel Chemical compound CCC1=CC=CC(N(C)C(N)=NC=2C3=CC=CC=C3C=CC=2)=C1 BFNCJMURTMZBTE-UHFFFAOYSA-N 0.000 description 1
- 229950001180 aptiganel Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 229960000722 brinzolamide Drugs 0.000 description 1
- HCRKCZRJWPKOAR-JTQLQIEISA-N brinzolamide Chemical compound CCN[C@H]1CN(CCCOC)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 HCRKCZRJWPKOAR-JTQLQIEISA-N 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 210000002987 choroid plexus Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229960001284 citicoline Drugs 0.000 description 1
- 229960004414 clomethiazole Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 description 1
- 229950006878 dextrorphan Drugs 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- QLTXKCWMEZIHBJ-PJGJYSAQSA-N dizocilpine maleate Chemical compound OC(=O)\C=C/C(O)=O.C12=CC=CC=C2[C@]2(C)C3=CC=CC=C3C[C@H]1N2 QLTXKCWMEZIHBJ-PJGJYSAQSA-N 0.000 description 1
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 229950010033 ebselen Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229950005455 eliprodil Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950002798 enlimomab Drugs 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003825 glutamate receptor antagonist Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- UMLFDVOHVJPDIZ-UHFFFAOYSA-N hydron;6-imidazol-1-yl-7-nitro-1,4-dihydroquinoxaline-2,3-dione;chloride Chemical compound Cl.[O-][N+](=O)C1=CC=2NC(=O)C(=O)NC=2C=C1N1C=CN=C1 UMLFDVOHVJPDIZ-UHFFFAOYSA-N 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 229960003998 ifenprodil Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- CHFSOFHQIZKQCR-UHFFFAOYSA-N licostinel Chemical compound N1C(=O)C(=O)NC2=C1C=C(Cl)C(Cl)=C2[N+](=O)[O-] CHFSOFHQIZKQCR-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960001078 lithium Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- MMIPFLVOWGHZQD-UHFFFAOYSA-N manganese(3+) Chemical compound [Mn+3] MMIPFLVOWGHZQD-UHFFFAOYSA-N 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FLOSMHQXBMRNHR-DAXSKMNVSA-N methazolamide Chemical compound CC(=O)\N=C1/SC(S(N)(=O)=O)=NN1C FLOSMHQXBMRNHR-DAXSKMNVSA-N 0.000 description 1
- 229960004083 methazolamide Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 230000004776 neurological deficiency Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 108010054442 polyalanine Proteins 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 108010052780 polyasparagine Proteins 0.000 description 1
- 108010077051 polycysteine Proteins 0.000 description 1
- 108010057904 polyisoleucine Proteins 0.000 description 1
- 108010026466 polyproline Proteins 0.000 description 1
- 108010000222 polyserine Proteins 0.000 description 1
- 108010033949 polytyrosine Proteins 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 229950000659 remacemide Drugs 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229950009825 selfotel Drugs 0.000 description 1
- 229950004070 sezolamide Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- YWAFNFGRBBBSPD-OCMLZEEQSA-M sodium;[[(2r,3s,4r,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].O[C@@H]1[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-OCMLZEEQSA-M 0.000 description 1
- YWAFNFGRBBBSPD-UHFFFAOYSA-M sodium;[[5-(4-amino-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound [Na+].OC1C(O)C(COP([O-])(=O)OP([O-])(=O)OCC[N+](C)(C)C)OC1N1C(=O)N=C(N)C=C1 YWAFNFGRBBBSPD-UHFFFAOYSA-M 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 229960000216 tenecteplase Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003451 thiazide diuretic agent Substances 0.000 description 1
- 229960005221 timolol maleate Drugs 0.000 description 1
- RBKASMJPSJDQKY-RBFSKHHSSA-N tirilazad Chemical compound O=C([C@@H]1[C@@]2(C)CC=C3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)CN(CC1)CCN1C(N=1)=CC(N2CCCC2)=NC=1N1CCCC1 RBKASMJPSJDQKY-RBFSKHHSSA-N 0.000 description 1
- 229960005155 tirilazad Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- UOCLRXFKRLRMKV-UHFFFAOYSA-N trolnitrate phosphate Chemical compound OP(O)(O)=O.OP(O)(O)=O.[O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O UOCLRXFKRLRMKV-UHFFFAOYSA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
Definitions
- This invention is related to prevention and treatment for brain and spinal cord injuries.
- the invention relates to osmotic agents and the methods of using osmotic agents to prevent and protect the brain and spinal cord injuries in patients.
- Central nervous system consisting of the brain and spinal cord is very vulnerable to injuries, such as hypoxia-ischemia, trauma, poisoning etc. Cerebral edema is a common pathway to all CNS injuries. Clinical prevention and treatment for CNS injuries induced edema includes intravenous administration of osmotic agent, diuretic, removal of cerebrospinal fluid, coticosterroids etc, however, the efficacy is temporary and limited. Current search for a neuroprotective treatment based on other molecular mechanisms has yielded a disappointing result including oxygen free radical scavengers, calcium channel blockers and glutamate receptor antagonists to monoclonal antibodies that attempt to curtail inflammatory cascades occurring in cerebral injuries etc.
- CSF cerebrospinal fluid
- the choroid plexuses are the main sites of CSF formation.
- the average rate of CSF formation is about 21 to 22 ml/hr, or approximately 500 ml/day.
- the CSF as a whole is renewed four or five times daily.
- the CSF formation is related to intracranial pressure. When the intracranial pressure is below about 70 mm H 2 O, CSF is not absorbed, and production increases.
- CSF CSF
- the known primary function of CSF appears to be a mechanical one; it serves as a kind of water jacket for the spinal cord and brain, protecting them from potentially injurious blows to the spinal column and skull and acute changes in venous pressure. Therefore, the brain and spinal cord are merged in the CSF.
- the CSF also serves as a buoyancy so that the brain and spinal cord virtually float in a CSF jacket with weight being greatly reduced.
- lymphatic fluid of the CNS the CSF is quite different from lymphatic fluid.
- lymphatic fluid contain higher concentration of protein.
- the interstitial fluid and lymphatic fluid pressure at capillary level is believed to be very low or even negative.
- the CSF occupies the subarachnoid space, it has free access to neurons and surrounding glia cells through the Vichow-robin space which is also known as the perivascular spaces. Smaller blood vessels, which centripetally penetrate into the brain proper, are accompanied by an extension of the subarachnoid space that forms the Virchow-Robin space and is filled with the CSF.
- the CSF is readily available to provide endless source of water to bath the CNS tissue; when the brain or spinal cord is injured by an initiating insult such as ischemia or trauma, the CSF infiltrates brain or spinal cord tissue through the injured cell membrane (or water channels) and causes the rapid development of edema. While excessive water inside the cell body is toxic, swelling of the tissue makes the Virchow-Robin space smaller and may even cause it to collapse, thereby compressing the small blood vessels and resulting in a obstruction of the blood flow, such as a “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop. These events result in irreversible cell death, tissue necrosis and liquefaction, finally neurological deficits and even brain death become clinical outcomes. Therefore dealing with cerebral edema is the key for preventing or treating CNS injuries.
- Crystal osmotic pressure can suck water from the edematous tissue.
- crystal osmotic agents such as glucose, mannitol or glycerin administration
- the main function of a colloidal osmotic agent such as albumin is for holding water.
- the colloidal osmotic agents can prevent the water from entering tissue.
- the efficacy of a colloidal osmotic agent should mainly depend on its water-holding capacity.
- the hydrostatic pressure is always the key contributor. It counteracts COP and promotes edema according to Starling's equation. However, it has less influence on crystal osmotic pressure.
- the ICP which is the hydrostatic pressure of the CSF, is often elevated when brain and spinal cord are injured.
- U.S. Pat. No. 6,500,809 to Frazer Glenn discloses a hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema.
- the inventor increase the colloidal osmotic pressure in an artificial CSF fluid, it will be difficult to reduce the ICP with the method invented. They did not increase the crystal osmotic pressure of the artificial CSF which is also very important and effective to treat cerebral edema.
- there are many disadvantages regarding to this artificial CSF regarding its use, store, safety, high cost for patient etc.
- Cerebral edema is a common pathway to all CNS injuries. All current clinical measures for prevention and treatment of CNS injuries induced edema only provide temporary and limited effect. Current search for a neuroprotective agent based on other molecular mechanisms has yielded a disappointing result.
- the CSF the very low colloidal osmotic pressure water solution
- ICP the very low colloidal osmotic pressure water solution
- the ICP promotes cerebral edema While excessive water inside the cell body is toxic, swelling of the tissue makes the Virchow-Robin space smaller, thereby compressing the small blood vessels and resulting in blood perfusion deficit, such as “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop.
- compositions and method for protecting brain and spinal cord may be used to treat neurological disorders, such as stroke, hypoxia-ischemia, hemorrhage, trauma, multiple sclerosis, seizure, infection, or poisoning.
- the compositions are also useful during open-heart surgery, aortic surgery, neurosurgery, shock, or other procedures where blood flow to the CNS is interrupted.
- composition and method provides an effective and simple approach to prevent and protect brain and spinal cord injuries.
- the composition is easy to make and is convenient to store and transport to anywhere. For example, it can be easily stored at room temperature for long time; the volume is small and can be easily transported to anywhere; Using patient's own CSF or simply using 5% Glucose or saline to dissolve the composition is simple and provides more chance for clinical physician to adjust the dosage according to patient condition.
- this invention also can reduce the cost of the treatment. Since the CSF is completely or partially removed, major water supply to cause the cerebral edema is eliminated. Therefore, the dosage is greatly reduced and efficacy is greatly enhanced. In addition, this invention provides more choices to make the composition, many of them are less expensive if large scale production is performed.
- This invention if combined with other known techniques such as controlled hypothermia, may significantly increase the length of time a patient can tolerate cerebral ischemia
- a patient treated according to this invention may survive invasive procedures performed on any part of the CNS without casing much injury, including areas of the brain that have not been surgically accessible prior to this invention such as brain stem. Additionally, procedures that require interruption of the blood flow, such as heart surgery, repair of aortic aneurysm, or any other surgery where systemic blood circulation is interrupted can be performed with increased safety.
- compositions and methods I have invented extend the therapeutic window for successfully resuscitating cardiac arrest from mere minutes to hours.
- this compositions and method are useful for screening neuroprotective agents developed based on other mechanisms.
- U.S. Pat. No. 6,500,809 to Frazer Glenn discloses a hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema
- the inventor increase the COP in an artificial CSF fluid, it will be difficult to reduce the ICP with the method invented. They did not increase the crystal osmotic pressure of the artificial CSF which is also very important, particularly when the treatment is delayed and quick treatment is needed. There are many disadvantages for this artificial CSF. First of all, putting albumin in an artificial CSF is not more advantageous than just dissolving the albumin in patient's own CSF.
- this hyperoncotic artificial cerebrospinal fluid has to be circulated at the rate of 1-100 ml/min, this may result in elevated ICP leading to deduct osmotic pressure generated by albumin based on Starling's equation.
- composition comprising osmotic agents and a method to prevent and treat brain and spinal cord injuries.
- a cannula is placed in through the dura into the subarachnoid spaces on the surface of the brain. Additional cannulas may be inserted into the lateral cerebral ventricles, the lumbar theca, and the cisterna magna. The CSF can be removed from any or all of these locations to remove edematous fluid.
- one cannula or two cannulas may be placed through a puncture in the lumbar theca or cisterna magna or the to the direct affected area.
- Synthetic poly-lysine has high water-holding capacity. For example, because of rich in lysine, animal proteins are considered high quality protein having higher water-holding capacity. Therefore Synthetic poly-lysine with larger molecular weight should have even higher water-holding capacity than any natural proteins. For a synthetic product, it is easier for quality control with no risk of deadly virus contamination.
- Poly-D-Lysine, poly-L-Lysine and Poly-ornithine with molecular weight between 70,000-150,000 have been frequently used to coat plate for culturing neurons. Therefore these agents have been proven to be safe to neurons and are preferred to serve as colloidal osmotic agents in our composition.
- Poly-D-Lysine hydrobromide from Sigma-Aldrich are found effective.
- Gelatin and collagen all have better water-holding capacity.
- Gelatin that has been used as a colloidal plasma volume substitute clinically is found effective.
- GELOFUSINE® (containing 4-14% gelatin) from Mill-pledge Ltd may also be injected directly to the subarachnoid spaces or may add some crystal osmotic agents or diluted with small amount of the patent's own CSF before injection.
- crystal osmotic agent and colloidal osmotic agent are mixed together.
- the crystal osmotic agent: colloidal osmotic agent should be 0.01-50 g: 100 g.
- the crystal osmotic agent and the colloidal osmotic agent may be kept in two separated containers and let the physician decide their proportion according to the patient's condition. It is preferred that the crystal osmotic agent can create osmolality of about 20-140 mOsm/L.
- the pressure generated by colloidal osmotic agent is no limit but depending on the viscosity after being dissolved in the CSF. However, it is preferred that colloidal osmotic agent can create a pressure of 28-40 mm Hg.
- the composition can be manufactured and contained in different quantities in small mapules that is ready for being dissolved in 5 ml, 10 ml, 20 ml, 50 ml, 100 ml of the CSF.
- Patient's CSF, 5% glucose and 0.9% sodium chloride have normal osmolality (280-310 mOsm/L), therefore can all be used to dissolve the composition.
- the dissolved composition will have higher osmolality required.
- the composition may be manufactured in a ready to use condition with crystal osmotic agent and colloidal osmotic agent mixed in 5% glucose, or 0.9% sodium chloride or artificial cerebrospinal fluid with final osmolality of 330-459 mOsm/L and COP of 2840 mm Hg.
- the osmolality of the CSF after being dissolved with composition should be about, but not limited to, 330-459 mOsm/L, it is preferred that colloidal osmotic agents can create a pressure of 2840 mm Hg.
- the CSF with composition is injected back to the subarachnoid space through one or more cannulas.
- the CSF loaded with high osmotic agents stay around the injured brain or spinal cord tissue for certain period. While the crystal osmotic agent suck the water from edematous tissue, the colloidal osmotic agent hold the water from entering the tissue again. If necessary, the treatment procedure can be repeated.
- the composition can be removed by withdrawing the CSF again from the subarachnoid space.
- administering agent to suppress production of CSF can be advantageous.
- agents that inhibit production of CSF include Furosemide (20-200 mg every 4-6 hours), and acetazolamide (0.25-2 g every 4-12 hours).
- CSF inhibiting agent can be administered intravenously, orally or by directly add to the invented composition injecting into subarachnoid space.
- compositions and methods herein can be advantageously combined with water channel blocker.
- water channel blocker For example, Mercury has been identified as a water channel blocker, therefore Mersalyl, the potent diuretic may be effective.
- compositions and methods herein can be advantageously combined with any of the agents used to treat stroke or other neurological deficiencies including: calcium channel blockers such as Nimodipine, and Flunarizine; calcium chelators, such as DP-b99; potassium channel blockers; Free radical scavengers—Antioxidants such as Ebselen, porphyrin catalytic antioxidant manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin, (MnTE-2-PyP (5+)), disodium 4-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide (NXY-059), N:-t-butyl-phenylnitrone or Tirilazad; GABA agonists including Clomethiazole; GABA receptor antagonists, glutamate antagonists, including AMPA antagonists such as GYKI 52466, NBQX,
- agents known to reduce cellular demand for energy such as phenytoin, barbital, or lithium may be added to the composition.
- compositions and methods can be combined with and enhance the efficiency of thrombolytic agents such as: recombinant tissue plasminogen activator (rtpA), streptokinase, and tenecteplase in dissolving thrombosis in management of stroke or myocardial infarction.
- thrombolytic agents such as: recombinant tissue plasminogen activator (rtpA), streptokinase, and tenecteplase in dissolving thrombosis in management of stroke or myocardial infarction.
- the acute spinal cord ischemia was induced in twenty-eight rabbits. Group one: control (4 rabbits). Group two: incomplete removal of the CSF (6 rabbits). Group three: treatment with composition I (6 rabbits).
- Isoflorane was given for anesthesia
- a PE-90 tubing was surgically implanted in the cisterna magna
- a PE-10 tubing was also implanted to the lumbar thecal sac in each rabbit.
- An abdominal incision was made and the aorta was isolated at the level of the renal artery.
- the aorta was cross-clamped by a clip just caudal to the left (lower) renal artery for one hour to produce spinal cord ischemic injury, then the clip was removed to resume blood supply.
- the global cerebral ischemia was induced in twenty-two rabbits. Group one: control (4 rabbits). Group two: treatment with composition I (6 rabbits). Group three: treatment with composition II (6 rabbits).
- 60 stupor: response with movements to pinching nailbed of hindlimb, open eyes, movements may be either purposeful or reflex.
- 100 coma: no movement on painful stimulation (pinching nailbed of hindlimb; should be confirmed on forelimbs as well).
- 50 abnormal spontaneous breathing (e.g., periodic gasps, irregular rhythm)
- Pupil size examine in room lighting and record diameters of pupil and iris (R/L)
- Corneal reflex Test with moist cotton swab, observe for eyelid closure (R/L)
- Auditory-palpebral (startle) reflex clap hands loudly and observe for motor response
- Gag reflex stimulate posterior pharynx and observe contraction of the soft palate under direct vision
- Carinal cough reflex stimulate carina of trachea with suction catheter and observe cough
- the score is 400. All rabbits died once disconnected from the ventilator.
- composition I and composition II average scores are about 30-60 (level of consciousness 0-30; respiratory pattern 0; cranial nerve function 0; motor and sensory function 0-30).
Abstract
A composition and method for treating and preventing injury to central nervous system tissue are provided. The composition is comprised of agents that can increase colloidal osmotic pressure and osmolality. The method comprise of: a). Withdrawing cerebrospinal fluid from the subarachnoid spaces around the tissue to be treated or protected and b). Injecting the composition into subarachnoid spaces.
Description
- This application is a continuation in part of application Ser. No. 09/962,009, filed Sep. 24, 2001, and a continuation in part of two continuation Application filed Nov. 7, 2003, the disclosure of which is incorporated by reference.
- 1. Field of the Invention
- This invention is related to prevention and treatment for brain and spinal cord injuries. In particular, the invention relates to osmotic agents and the methods of using osmotic agents to prevent and protect the brain and spinal cord injuries in patients.
- 2. Background Information
- Central nervous system (CNS) consisting of the brain and spinal cord is very vulnerable to injuries, such as hypoxia-ischemia, trauma, poisoning etc. Cerebral edema is a common pathway to all CNS injuries. Clinical prevention and treatment for CNS injuries induced edema includes intravenous administration of osmotic agent, diuretic, removal of cerebrospinal fluid, coticosterroids etc, however, the efficacy is temporary and limited. Current search for a neuroprotective treatment based on other molecular mechanisms has yielded a disappointing result including oxygen free radical scavengers, calcium channel blockers and glutamate receptor antagonists to monoclonal antibodies that attempt to curtail inflammatory cascades occurring in cerebral injuries etc.
- The existence of the cerebrospinal fluid (CSF) is a unique feature of the CNS. In an adult human, the CSF volume ranges from about 52 to 160 ml (mean 140 ml), occupying 10 percent of the intra-cranial and intra-spinal volume. The choroid plexuses are the main sites of CSF formation. The average rate of CSF formation is about 21 to 22 ml/hr, or approximately 500 ml/day. The CSF as a whole is renewed four or five times daily. The CSF formation is related to intracranial pressure. When the intracranial pressure is below about 70 mm H2O, CSF is not absorbed, and production increases. To date, there is no definite evidence suggesting that the CSF is actively involved in the metabolism of the cells of the brain and spinal cord. The known primary function of CSF appears to be a mechanical one; it serves as a kind of water jacket for the spinal cord and brain, protecting them from potentially injurious blows to the spinal column and skull and acute changes in venous pressure. Therefore, the brain and spinal cord are merged in the CSF. The CSF also serves as a buoyancy so that the brain and spinal cord virtually float in a CSF jacket with weight being greatly reduced.
- Although some researchers regard the CSF as lymphatic fluid of the CNS, the CSF is quite different from lymphatic fluid. First of all, in the peripheral tissues and organs, interstitial fluid and lymphatic fluid are separated, lymphatic fluid contain higher concentration of protein. Second, the interstitial fluid and lymphatic fluid pressure at capillary level is believed to be very low or even negative. However, although the CSF occupies the subarachnoid space, it has free access to neurons and surrounding glia cells through the Vichow-robin space which is also known as the perivascular spaces. Smaller blood vessels, which centripetally penetrate into the brain proper, are accompanied by an extension of the subarachnoid space that forms the Virchow-Robin space and is filled with the CSF. Importantly, the CSF is mainly composed of water and electrolytes. Although, the osmolality of the CSF is about 289 mOsm/L (almost equal to the plasma), but the colloidal pressure (COP) is very low because of the extremely low protein concentration. In addition, the intracranial pressure (ICP) is normally ranged between 80-180 mm H2O.
- It has been known that after cardiac arrest and global ischemia, the brain suffers a “no-reflow” phenomenon. In the 1960s, Ames produced global cerebral ischemia for 6 minutes in rabbits followed by carbon black ink infusion. Ames found that a large amount of the brain suffered from perfusion deficits. Similar to the “no-reflow” phenomenon, post-ischemic or post-traumatic “hypoperfusion” has also been documented after spinal cord and brain injuries.
- We have proposed that these unique physiological and anatomic features of the CNS place the brain and spinal cord in a very delicate edema prone position and play an important role in the vulnerability of the brain and spinal cord.
- Our hypothesis is: The CSF is readily available to provide endless source of water to bath the CNS tissue; when the brain or spinal cord is injured by an initiating insult such as ischemia or trauma, the CSF infiltrates brain or spinal cord tissue through the injured cell membrane (or water channels) and causes the rapid development of edema. While excessive water inside the cell body is toxic, swelling of the tissue makes the Virchow-Robin space smaller and may even cause it to collapse, thereby compressing the small blood vessels and resulting in a obstruction of the blood flow, such as a “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop. These events result in irreversible cell death, tissue necrosis and liquefaction, finally neurological deficits and even brain death become clinical outcomes. Therefore dealing with cerebral edema is the key for preventing or treating CNS injuries.
- The osmosis in a living creature is not fully understood. Crystal osmotic pressure can suck water from the edematous tissue. For example, in clinic, while crystal osmotic agents such as glucose, mannitol or glycerin administration have strong and quick effect. However, the main function of a colloidal osmotic agent such as albumin is for holding water. The colloidal osmotic agents can prevent the water from entering tissue. The efficacy of a colloidal osmotic agent should mainly depend on its water-holding capacity.
- In the formation of edema, the hydrostatic pressure is always the key contributor. It counteracts COP and promotes edema according to Starling's equation. However, it has less influence on crystal osmotic pressure. Importantly, in addition to the low colloidal pressure of the CSF, the ICP which is the hydrostatic pressure of the CSF, is often elevated when brain and spinal cord are injured.
- U.S. patent filed Sep. 24, 2001 from Yanming Wang discloses a composition and treatment method for brain and spinal cord injuries.
- Two U.S. patents of continuation of Sep. 24, 2001 from Yanming Wang filed Nov. 7, 2003 discloses compositions and treatment methods for brain and spinal cord injuries.
- U.S. Pat. No. 6,500,809 to Frazer Glenn discloses a hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema. Although the inventor increase the colloidal osmotic pressure in an artificial CSF fluid, it will be difficult to reduce the ICP with the method invented. They did not increase the crystal osmotic pressure of the artificial CSF which is also very important and effective to treat cerebral edema. In addition, there are many disadvantages regarding to this artificial CSF regarding its use, store, safety, high cost for patient etc.
- A series of patents, U.S. Pat. Nos. 4,981,691, 4,758,431, 4,445,887, 4,445,500, and 4,393,863 to Osterholm disclose a fluorocarbon solution for treatment of hypoxic-ischemic neurological tissue.
- Cerebral edema is a common pathway to all CNS injuries. All current clinical measures for prevention and treatment of CNS injuries induced edema only provide temporary and limited effect. Current search for a neuroprotective agent based on other molecular mechanisms has yielded a disappointing result.
- Our hypothesis is: the two factors, i.e. the CSF and ICP, are the main reasons to cause the vulnerability of the CNS to injuries. The CSF, the very low colloidal osmotic pressure water solution, is readily available to provide endless source of water to bath the CNS tissue to cause the rapid development of edema when the brain or spinal cord is injured. The ICP promotes cerebral edema While excessive water inside the cell body is toxic, swelling of the tissue makes the Virchow-Robin space smaller, thereby compressing the small blood vessels and resulting in blood perfusion deficit, such as “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop. These cascade events result in irreversible cell death, tissue necrosis and liquefaction, finally neurological deficits and even brain death become clinical outcomes. Therefore removing the CSF and increasing the osmotic pressure of the remaining CSF will reduce the cerebral edema herein increasing the cerebral flow and protecting the brain and spinal cord tissue.
- This invention provides compositions and method for protecting brain and spinal cord. Compositions according to this invention may be used to treat neurological disorders, such as stroke, hypoxia-ischemia, hemorrhage, trauma, multiple sclerosis, seizure, infection, or poisoning. The compositions are also useful during open-heart surgery, aortic surgery, neurosurgery, shock, or other procedures where blood flow to the CNS is interrupted.
- I have found the formulations I have used are effective when it is dissolved in patient's own CSF or simply dissolved in 5% Glucose or saline and applied to the subarachnoid spaces after the cerebrospinal fluid has been removed completely or partially from the subarachnoid spaces. These methods are effective to treat injured CNS tissue or to protect it from continuing damage after injury. To treat or prevent the CNS injuries, the composition will be dissolved in certain amount of the patient's own CSF or simply dissolved in 5% Glucose or saline and injected into subarachnoid spaces increasing the osmotic pressure around the injured CNS tissue to adsorb water from the edematous tissue and prevent water from further entering injurious tissue. Elimination of this cerebral edema prevents the onset of the “no-reflow” phenomenon or “hypoperfusion”, and protects the CNS tissue making it resistant to injuries, and lengthening the therapeutic window for all other therapies.
- There are many advantages to the compositions and method I have discovered.
- 1. the composition and method provides an effective and simple approach to prevent and protect brain and spinal cord injuries.
- 2. it improves the efficacy of existing treatments for stroke, head trauma, and other invasive procedures. Administering an effective composition through subarachnoid spaces after removing the CSF according to this invention will increase the therapeutic window, the period of time in which any other treatment, including thrombolytic agents can be used. For example, tPA, the only FDA approved medication for stroke, is a thrombolytic agent targeted on dissolving the blood clots that led to the stroke. tPA is now only approved for use within 3 hours after onset of ischemia. When used in combination with the instant composition and method, the therapeutic window for all known treatments now used for supporting CNS tissue will be much longer. Another example is this invention if used before, during and after brain and spinal cord surgery, a quicker and better recovery result can be achieved.
- 3. the composition is easy to make and is convenient to store and transport to anywhere. For example, it can be easily stored at room temperature for long time; the volume is small and can be easily transported to anywhere; Using patient's own CSF or simply using 5% Glucose or saline to dissolve the composition is simple and provides more chance for clinical physician to adjust the dosage according to patient condition.
- 4. this invention also can reduce the cost of the treatment. Since the CSF is completely or partially removed, major water supply to cause the cerebral edema is eliminated. Therefore, the dosage is greatly reduced and efficacy is greatly enhanced. In addition, this invention provides more choices to make the composition, many of them are less expensive if large scale production is performed.
- 5. This invention, if combined with other known techniques such as controlled hypothermia, may significantly increase the length of time a patient can tolerate cerebral ischemia A patient treated according to this invention may survive invasive procedures performed on any part of the CNS without casing much injury, including areas of the brain that have not been surgically accessible prior to this invention such as brain stem. Additionally, procedures that require interruption of the blood flow, such as heart surgery, repair of aortic aneurysm, or any other surgery where systemic blood circulation is interrupted can be performed with increased safety.
- 6. The compositions and methods I have invented extend the therapeutic window for successfully resuscitating cardiac arrest from mere minutes to hours. In addition, this compositions and method are useful for screening neuroprotective agents developed based on other mechanisms.
- As we have discussed in the background information, two factors make the CNS vulnerable to injuries, i.e. the CSF itself is a low colloidal osmotic pressure water solution, the ICP, the hydrostatic pressure of the CSF can deduct the force of colloidal osmotic pressure to promote edema The CSF is readily available to provide endless source of water to bath the CNS tissue; when the brain or spinal cord is injured by an initiating insult such as ischemia or trauma, the CSF infiltrates brain or spinal cord tissue through the injured cell membrane (or water channels) and causes the rapid development of edema While excessive water inside the cell body is toxic, swelling of the tissue makes the Virchow-Robin space smaller and may even cause it to collapse, thereby compressing the small blood vessels and resulting in a obstruction of the blood flow, such as a “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop. This failure of circulation results in continuing damage to CNS tissue after the interruption of blood flow is reversed leading to irreversible damage and eventually cell death, tissue necrosis and liquefaction, finally neurological deficits and even brain death become clinical outcomes.
- Therefore dehydrating the edematous cerebral tissue is the most important issue to prevent and treat the brain and spinal cord injuries. As we all know, intravenously infusion of osmotic agents only provide temporary and limited effect, the reasonable strategy should target the CSF and ICP, i.e. decreasing the ICP and increasing the osmotic pressure of the CSF.
- U.S. Pat. No. 6,500,809 to Frazer Glenn discloses a hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema Although the inventor increase the COP in an artificial CSF fluid, it will be difficult to reduce the ICP with the method invented. They did not increase the crystal osmotic pressure of the artificial CSF which is also very important, particularly when the treatment is delayed and quick treatment is needed. There are many disadvantages for this artificial CSF. First of all, putting albumin in an artificial CSF is not more advantageous than just dissolving the albumin in patient's own CSF. Although albumin is good for maintain colloidal osmotic pressure, it is expensive and may be risky for being infected by HIV, Hepatitis virus B etc if the albumin is from human. In addition, it is not convenient to store and transfer this hyperoncotic artificial cerebrospinal fluid because it requires large volume of it to circulate in the cranium; Manufacturing a hyperoncotic artificial cerebrospinal fluid and circulating it are complicated and will have to add additional cost to a patient without enhancing drug effects. Although as the inventor stated in claim31, the hyperoncotic artificial cerebrospinal fluid can be ultrafiltered and recirculated, the procedure is complicated and it seems wasting albumin is inevitable. According to the claim 21, this hyperoncotic artificial cerebrospinal fluid has to be circulated at the rate of 1-100 ml/min, this may result in elevated ICP leading to deduct osmotic pressure generated by albumin based on Starling's equation.
- I have invented a composition comprising osmotic agents and a method to prevent and treat brain and spinal cord injuries.
- To treat or prevent the brain and spinal cord injuries, first, removing the CSF to reduce the ICP and cut off the major water supply to cerebral tissue, then using part of the removed CSF as a solvent to dissolve the invented composition, second, injecting the composition which is dissolved by patient's own CSF to the affected area of the CNS tissue. Since the CSF injected back is relatively small portion of the whole CSF removed, the ICP will not be increased.
- For maximum CNS tissue protection, two small holes are drilled on the skull, the dura is punctured, and a cannula is placed in through the dura into the subarachnoid spaces on the surface of the brain. Additional cannulas may be inserted into the lateral cerebral ventricles, the lumbar theca, and the cisterna magna. The CSF can be removed from any or all of these locations to remove edematous fluid. Optionally, for the treatment or prevention of localize injuries such as spinal cord injury, stroke, one cannula or two cannulas may be placed through a puncture in the lumbar theca or cisterna magna or the to the direct affected area.
- In the instant method, the CSF (usually 5-200 ml) is withdrawn from the cranium and lumbar theca depending on the location of the injuries. If whole CNS needs to be protected such as cardiac arrest or during the cardiac surgery, the CSF should be removed as completely as possible. But for a localized injury such as stroke, head trauma, or for prevention of a localized injury during neurosurgery or aortic surgery, beneficial effects can be achieved upon removal of a lesser volume of the CSF. Although mechanically withdrawing CSF alone is not sufficient enough to achieve the neuroprotective effect, it reduces the ICP and cut off the major water supply to the cerebral tissue. By removing the CSF, the ICP can be reduced even to 0 mm H2O if necessary. Meanwhile, the CSF removed is saved for dissolving the composition described below and for injecting back. It is very difficult to completely remove all the CSF, the residual aqueous CSF after manual withdrawal can still cause edema and resultant “hypoperfusion” or “no-reflow” phenomenon, significantly decreasing the protective effect because it is a continued source of edematous fluid that can cause delayed or recurring injury. Therefore, our composition is needed.
- The composition consists of both crystal and colloidal osmotic agents, it can be dry power form or liquid form. Although, many crystal osmotic agents can be chosen, such as glucose, mannitol, sorbitol, glycerin, sodium chloride, saccharose, saccharides, those used in clinic are preferred. Colloidal osmotic agents can be chosen from synthetic poly-amino acid, gelatin and collagen. Many poly-amino acids are commercially available, such as Poly-alanine, Poly-arginine, Poly-asparagine, Poly-cysteine, Poly-glutamate, Poly-histidine, Poly-isoleucine, Poly-ornithine, Poly-proline, Poly-Serine, Poly-tyrosine. Synthetic poly-lysine has high water-holding capacity. For example, because of rich in lysine, animal proteins are considered high quality protein having higher water-holding capacity. Therefore Synthetic poly-lysine with larger molecular weight should have even higher water-holding capacity than any natural proteins. For a synthetic product, it is easier for quality control with no risk of deadly virus contamination. Poly-D-Lysine, poly-L-Lysine and Poly-ornithine with molecular weight between 70,000-150,000 have been frequently used to coat plate for culturing neurons. Therefore these agents have been proven to be safe to neurons and are preferred to serve as colloidal osmotic agents in our composition. Poly-D-Lysine hydrobromide from Sigma-Aldrich are found effective. Gelatin and collagen all have better water-holding capacity. Gelatin that has been used as a colloidal plasma volume substitute clinically is found effective. GELOFUSINE® (containing 4-14% gelatin) from Mill-pledge Ltd may also be injected directly to the subarachnoid spaces or may add some crystal osmotic agents or diluted with small amount of the patent's own CSF before injection.
- To make the composition, crystal osmotic agent and colloidal osmotic agent are mixed together. The crystal osmotic agent: colloidal osmotic agent should be 0.01-50 g: 100 g. Optionally, the crystal osmotic agent and the colloidal osmotic agent may be kept in two separated containers and let the physician decide their proportion according to the patient's condition. It is preferred that the crystal osmotic agent can create osmolality of about 20-140 mOsm/L. The pressure generated by colloidal osmotic agent is no limit but depending on the viscosity after being dissolved in the CSF. However, it is preferred that colloidal osmotic agent can create a pressure of 28-40 mm Hg. The composition can be manufactured and contained in different quantities in small mapules that is ready for being dissolved in 5 ml, 10 ml, 20 ml, 50 ml, 100 ml of the CSF. Patient's CSF, 5% glucose and 0.9% sodium chloride have normal osmolality (280-310 mOsm/L), therefore can all be used to dissolve the composition. The dissolved composition will have higher osmolality required. Optionally, the composition may be manufactured in a ready to use condition with crystal osmotic agent and colloidal osmotic agent mixed in 5% glucose, or 0.9% sodium chloride or artificial cerebrospinal fluid with final osmolality of 330-459 mOsm/L and COP of 2840 mm Hg.
- To use the composition to prevent or to treat brain or spinal cord injuries, dissolving the composition in patient's own CSF, the clinical physician can decide the amount of the CSF being removed and dosage of the composition. Usually 5-160 ml of the patient's own CSF can be obtained as a solvent to dissolve the composition. For example, if a localized injury such as a spinal cord trauma, 5-20 ml of the patient's own CSF may be used. The CSF can be centrifuged and the supernatant can be used in case of blood in the CSF. Alternatively, simply using 5% glucose or 0.9% sodium chloride. The osmolality of the CSF after being dissolved with composition should be about, but not limited to, 330-459 mOsm/L, it is preferred that colloidal osmotic agents can create a pressure of 2840 mm Hg. After shaking well, the CSF with composition is injected back to the subarachnoid space through one or more cannulas. The CSF loaded with high osmotic agents stay around the injured brain or spinal cord tissue for certain period. While the crystal osmotic agent suck the water from edematous tissue, the colloidal osmotic agent hold the water from entering the tissue again. If necessary, the treatment procedure can be repeated. After patient is recovered, the composition can be removed by withdrawing the CSF again from the subarachnoid space.
- Meanwhile, administering agent to suppress production of CSF can be advantageous. There are many known agents that inhibit production of CSF. All diuretics, include Furosemide (20-200 mg every 4-6 hours), and acetazolamide (0.25-2 g every 4-12 hours). Other agents known to suppress formation of CSF include: beta blocking agents such as isopranolol, and timolol maleate; and calcium channel blockers such as brinzolamide, dorzolamide, methazolamide, sezolamide, lantano-prost, and bis (carbonyl) amidothiadiazole sulfonamides; and carbonic acid anhydrase inhibitors such as triamterene, spironolactone, thiazides, and, Na and K-ATPase inhibitors. This CSF inhibiting agent can be administered intravenously, orally or by directly add to the invented composition injecting into subarachnoid space.
- The recent discovery of water channels in the CNS provides a better explanation for the mechanism of brain edema Aquapprin-1 (AQP1), Aquapprin-4 (AQP4), Aquapprin-5 (AQP5), Aquapprin-9 (AQP9) water channels have been identified in CNS, and believed to play an important role in the development of cerebral edema The subarachnoid space is just like a reservoir containing the CSF water providing endless water supply for the CNS tissue. When injury occurs, CSF readily available to penetrate CNS tissues through water channels, while intracellular water unbalance exert direct toxicity to cells, swelling of the tissue around the Virchow-Robin space results in “hypoperfusion” or even “no-reflow” phenomenon, which prolongs the original ischemic duration, blocks collateral circulation and induces a feedback loop. Therefore the compositions and methods herein can be advantageously combined with water channel blocker. For example, Mercury has been identified as a water channel blocker, therefore Mersalyl, the potent diuretic may be effective.
- The compositions and methods herein can be advantageously combined with any of the agents used to treat stroke or other neurological deficiencies including: calcium channel blockers such as Nimodipine, and Flunarizine; calcium chelators, such as DP-b99; potassium channel blockers; Free radical scavengers—Antioxidants such as Ebselen, porphyrin catalytic antioxidant manganese (III) meso-tetrakis (N-ethylpyridinium-2-yl) porphyrin, (MnTE-2-PyP (5+)), disodium 4-[(tert-butylimino) methyl] benzene-1,3-disulfonate N-oxide (NXY-059), N:-t-butyl-phenylnitrone or Tirilazad; GABA agonists including Clomethiazole; GABA receptor antagonists, glutamate antagonists, including AMPA antagonists such as GYKI 52466, NBQX, YM90K, YN872, ZK-200775 MPQX, Kainate antagonist SYM 2081, NMDA antagonists, including competitive NMDA antagonists such as CGS 19755 (Selfotel); NMDA channel blockers including Aptiganel (Cerestat), CP-101,606, Dextrorphan, destromethorphan, magnesium, metamine, MK-801, NPS 1506, and Remacemide; Glycine site antagonists including ACEA 1021, and GV 150026; polyamine site antagonists such as Eliprodil, and Ifenprodil; and adenosine receptor antagonists; Growth factors such as Fibroblast Growth Factor (bFGF), Glial cell line derived neurotrophic factor (GDNF), brain derived neurotrophic factor, insulin like growth factor, or neurotrophin; Leukocyte adhesion inhibitors such as Anti ICAM antibody (Enlimomab) and Hu23F2G; Nitric oxide inhibitors including Lubeluzole; opiod antagonists, such as Naloxone, Nalmefenem, Phosphatidylcholine precursor, Citicoline (CDP-coline); Serotonin agonists including Bay x 3072; Sodium channel blockers such as Fosphenytoin, Lubeluzole, and 619C89; Potassium channel openers such as BMS-204352; anti-inflamatory agents; protein kinase inhibitors, and other agents whose mechanism of action is unknown or uncertain including: Piracetam and albumin. Other active agents, that provide energy to cells, such as ATP, co-enzyme A, co-enzyme Q, or cytochrome C may be added. Similarly, agents known to reduce cellular demand for energy, such as phenytoin, barbital, or lithium may be added to the composition.
- The compositions and methods can be combined with and enhance the efficiency of thrombolytic agents such as: recombinant tissue plasminogen activator (rtpA), streptokinase, and tenecteplase in dissolving thrombosis in management of stroke or myocardial infarction.
- Treatment of Spinal Cord Ischemia With our Method and Compositions
- The acute spinal cord ischemia was induced in twenty-eight rabbits. Group one: control (4 rabbits). Group two: incomplete removal of the CSF (6 rabbits). Group three: treatment with composition I (6 rabbits).
- Isoflorane was given for anesthesia A PE-90 tubing was surgically implanted in the cisterna magna, a PE-10 tubing was also implanted to the lumbar thecal sac in each rabbit. An abdominal incision was made and the aorta was isolated at the level of the renal artery. The aorta was cross-clamped by a clip just caudal to the left (lower) renal artery for one hour to produce spinal cord ischemic injury, then the clip was removed to resume blood supply.
- For group one control, the CSF was not removed.
- For group two, at 15 minutes after ischemia, the CSF was removed as completely as possible (usually 0.8-1.2 ml CSF could be withdrawn), then 0.1 ml CSF was immediately returned. To further ensure that the 0.1 ml of CSF returned to reach the lumber spinal cord uniformly, the rabbits on the plane operating board were kept in a slightly tilted position with head up (10 degrees), The ICP was maintained at 0-10 cm H2O.
- For group three, at 15 minutes after ischemia, the CSF was removed as completely as possible (usually 0.8-1.2 ml CSF could be withdrawn). After the CSF removal, 0.5 ml of the CSF was used to dissolve composition I {40 mg Poly-D-lysine hydrobromide (molecular weight between 70,000-150,000) and 12.5 mg mannitol}, then was injected back through the PE-10 tubing. The ICP was maintained at 0-70 cm H2O during the ischemia.
- At one week after ischemic injury, the rabbits were tested for behavioral deficit (grade 0: complete recovery; grade 1: able to stand, but unable to walk normally; grade 2: good movement of the hind limbs, but unable to stand; grade 3: spastic paraplegia with slight movement of the hind limbs; grade 4: spastic paraplegia with no movement to the hind limbs).
- The result is summarized as following: At one week after ischemia, in group one and group two, all rabbits showed spastic paraplegia with no movement to the hind limbs (grade 4); In group three, no apparent deficit could be observed, all of rabbits walked and moved smoothly (grade 0).
- Treatment for Brain Ischemia With our Method and Compositions
- The global cerebral ischemia was induced in twenty-two rabbits. Group one: control (4 rabbits). Group two: treatment with composition I (6 rabbits). Group three: treatment with composition II (6 rabbits).
- Isoflorane was given for anesthesia. The trachea was incubated and connected to mechanical intermittent positive-pressure ventilation (tidal volume 30 ml, rate 50/min, O2 concentration 30%). A cannula was surgically positioned in the cisterna magna in each rabbit. A hole of 3 mm in diameter (4 mm lateral to midline and 3 mm posterior to the bregma) was drilled on each side of the skull, a cannula were positioned in the hole on each side through puncture. An arterial line was cannulated through femoral artery for monitoring blood pressure. A femoral vein was also cannulated for withdrawing and infusing blood. Four blood vessels (two common carotid arteries and two vertebrate arteries) were isolated and occluded for one hour with arterial clips to produce brain ischemia In order to produce complete global ischemia, 60-120 ml of blood was withdrawn to lower the blood pressure simultaneously. The mean blood pressure was maintained between 30-40 mmHg.
- In group one, at 10 minutes after the global ischemia, 0.8-1.2 ml of CSF was withdrawn from caunnulas in cisterna magna and holes of the skull, then 0.30.6 ml of CSF was returned through the these caunnulas. The intracranial pressure was maintained at 0-70 cm H2O In group two, at 10 minutes after the global ischemia, 0.8-1.2 ml of CSF was withdrawn from caunnulas in cisterna magna and holes of the skull. After the CSF removal, 0.8 ml of the CSF was used to dissolve our composition I {64 mg Poly-D-lysine hydrobromide (molecular weight between 70,000-150,000) and 20 mg mannitol}, then was injected back through the caunnulas. The ICP was maintained at 0-70 cm H20.
- In group three, at 10 minutes after the global ischemia, 0.8-1.2 ml of CSF was withdrawn from caunnulas in cisterna magna and holes of the skull. After the CSF removal, 0.8 ml of the CSF was used to dissolve our composition 1 (64 mg gelatin, 0.72 mg glucose), then was injected back through the caunnulas. The ICP was maintained at 0-70 cm H20.
- At one hours of the global brain ischemia, the arterial clips were removed and then followed by blood infusion. Phenylephrine (10 mg in 100 ml saline) was given to increase and maintain mean blood pressure between 80-100 mmHg. At 24 hours after ischemic injury, the rabbits were tested for behavioral deficit by the following criteria: Maximum Score=400 (meaning brain death or death); Minimum Score=0 (meaning normal brain)
- 1. Level of consciousness
- 0=complete awareness of auditory stimuli.
- 30=clouded: apparently conscious but drowsy or intermittently irritable on clapping hands and pinching nailbeds of hindlegs.
- 60=stupor: response with movements to pinching nailbed of hindlimb, open eyes, movements may be either purposeful or reflex.
- 100=coma: no movement on painful stimulation (pinching nailbed of hindlimb; should be confirmed on forelimbs as well).
- 2. Respiratory pattern
- 0=normal rate and rhythm.
- 50=abnormal spontaneous breathing (e.g., periodic gasps, irregular rhythm)
- 75=breathing, but not enough to maintain normal arterial blood gases.
- 100=apnea: complete absence of spontaneous respiratory efforts
- 3. Cranial nerve function
- Pupil size: examine in room lighting and record diameters of pupil and iris (R/L)
- 0=normal: 3-7 mm diameter
- 10=abnormal: greater than 7 mm
- 15=severely abnormal: greater than 10, pinpoint, or new anisocoria
- Papillary response to light: use flashlight (R/L)
- 0=normal
- 10=sluggish
- 15=absent
- Eyelid reflex:
- 0=normal
- 10=sluggish
- 15=absent
- Corneal reflex: Test with moist cotton swab, observe for eyelid closure (R/L)
- 0=normal
- 10=sluggish
- 15=absent
- Swallow reflex:
- 0=normal:
- 10=absent
- Auditory-palpebral (startle) reflex: clap hands loudly and observe for motor response
- 0=normal
- 10=no response
- Gag reflex: stimulate posterior pharynx and observe contraction of the soft palate under direct vision
- 0=normal
- 10=absent
- Carinal cough reflex: stimulate carina of trachea with suction catheter and observe cough
- 0=normal
- 10=absent
- 4. Motor and sensory function
- Muscle stretch reflex
- 0=normal in all extremities
- 10=increased or absent 1-3 extremities
- 25=absent in all extremities
- Motor response to painful stimulus: Pinch each limb, observe for withdrawal response.
- 0=normal 4
- 10=no response
- 25=coma (no test required)
- Positioning: place rabbit in left lateral decubitus position and observe position assumed.
- 0=normal
- 10=mildly abnormal or intermittent running movements
- 25=markedly abnormal: opistotonus, fixed flexion, total flaccidity, severe running movements
- Muscle tone: Pick up each extremity and release; observe
- 0=normal
- 10=1 or 2 extremities stiff or flaccid
- 25=3 or 4 extremities stiff or flaccid
- The results are as follow:
- In group one, the score is 400. All rabbits died once disconnected from the ventilator.
- However group two and three treated with composition I and composition II, average scores are about 30-60 (level of consciousness 0-30; respiratory pattern 0; cranial nerve function 0; motor and sensory function 0-30).
- While my above description contains many specifics, these should not be construed as limitations on the scope of the invention, but rather as illustrative examples.
Claims (26)
1. A neuroprotective composition for protecting the central nervous system of a mammal comprising Poly-amino Acid.
2. A neuroprotective composition for protecting the central nervous system of a mammal comprising essentially Poly-amino Acid.
3. A neuroprotective composition for protecting the central nervous system of a mammal comprising % 0.1-20% Poly-amino Aci
4. A neuroprotective composition for protecting the central nervous system of a mammal comprising Poly-Lysine.
5. A neuroprotective composition for protecting the central nervous system of a mammal comprising essentially Poly-Lysine.
6. A neuroprotective composition for protecting the central nervous system of a mammal comprising Poly-D-Lysine.
7. A neuroprotective composition for protecting the central nervous system of a mammal comprising Poly-L-Lysine.
8. A neuroprotective composition for protecting the central nervous system of a mammal comprising Poly-Lysine with molecular weight between 70,000-150,000.
9. A neuroprotective composition for protecting the central nervous system of a mammal comprising gelatin.
10. A neuroprotective composition for protecting the central nervous system of a mammal comprising essentially gelatin.
11. A neuroprotective composition for protecting the central nervous system of a mammal comprising collagen.
12. A neuroprotective composition for protecting the central nervous system of a mammal comprising essentially collagen.
13. A neuroprotective composition for protecting the central nervous system of a mammal comprising a combination of Poly-amino Acid and a crystal osmotic agent.
14. A neuroprotective composition for protecting the central nervous system of a mammal comprising a combination of gelatin and a crystal osmotic agent.
15. A neuroprotective composition for protecting the central nervous system of a mammal comprising a combination of collagen and a crystal osmotic agent.
16. A neuroprotective composition according to claim 13 ,14 and 15 wherein said crystal osmotic agent is mannitol.
17. A neuroprotective composition according to claim 13 ,14 and 15 wherein said crystal osmotic agent is glucose.
18. A solution that can generate a colloidal osmotic pressure between 1-40 mm Hg with said neuroprotective composition according to claim 1 to 17.
19. A solution that can generate a colloidal osmotic pressure between 140 mm Hg and osmolality between 289-459 mOsm/L with said neuroprotective composition according to claim 1 to 17.
20. A method for protecting Central Nervous System tissue in need of such protection in mammal, comprising the steps of:
a). Withdrawing a volume of cerebrospinal fluid from the subarachnoid space,
b). Injecting a said neuroprotective composition according to claim 1 to 17 which is dissolved by certain amount of said cerebrospinal fluid into said subarachnoid space.
21. A method for protecting Central Nervous System tissue in need of such protection in mammal, comprising the steps of:
a). Withdrawing a volume of cerebrospinal fluid from the subarachnoid space,
b). Injecting a said solution according to claim 18 and 19 into said subarachnoid space.
22. A method for protecting Central Nervous System tissue in need of such protection in mammal according to claim 20 and 21, comprising added step of administering a CSF production-suppressing agent.
23. A method for protecting Central Nervous System tissue in need of such protection in mammal according to claim 20 and 21, comprising added step of administering a water channel blocker, such as Mersalyl.
24. A method for protecting Central Nervous System tissue in need of such protection in mammal according to claim 20 and 21, comprising added step of administering an effective amount of agent selected from the group consisting of: calcium channel blockers, calcium chelators, potassium channel blockers, free radical scavengers, antioxidants, GABA agonists, GABA receptor antagonists, glutamate antagonists, NMDA antagonists, NMDA channel blockers, glycine site antagonists, polyamine site antagonists, adenosine receptor antagonists, growth factors, Glial cell line derived neurotrophic factor (GDNF), brain derived neurotrophic factor, insulin like growth factor, leukocyte adhesion inhibitors, nitric oxide inhibitors, opiod antagonists, Serotonin agonists, sodium channel blockers, potassium channel openers, anti-inflamatory agents, and protein kinase inhibitors to said mammal.
25. A method for treating stroke in a mammal requiring such treatment according to claim 20 and 21 comprising added step of Administering a thrombolytic agent to said mammal in an amount effective to restore blood flow to central nervous system tissue.
26. A method according to claim 25 wherein said thrombolytic agent is recombinant tissue plasminogen activator (rt-PA).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/744,114 US20040138125A1 (en) | 2001-09-24 | 2003-12-23 | Composition and method to prevent and treat brain and spinal cord injuries |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/962,009 US6683066B2 (en) | 2001-09-24 | 2001-09-24 | Composition and treatment method for brain and spinal cord injuries |
US10/744,114 US20040138125A1 (en) | 2001-09-24 | 2003-12-23 | Composition and method to prevent and treat brain and spinal cord injuries |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/962,009 Continuation-In-Part US6683066B2 (en) | 2001-09-24 | 2001-09-24 | Composition and treatment method for brain and spinal cord injuries |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040138125A1 true US20040138125A1 (en) | 2004-07-15 |
Family
ID=25505317
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/962,009 Expired - Fee Related US6683066B2 (en) | 2001-09-24 | 2001-09-24 | Composition and treatment method for brain and spinal cord injuries |
US10/703,320 Abandoned US20040142905A1 (en) | 2001-09-24 | 2003-11-07 | Compositions and treatment method for brain and spinal cord injuries |
US10/703,830 Abandoned US20040142906A1 (en) | 2001-09-24 | 2003-11-07 | Conpositions and method to prevent and treat brain and spinal cord injuries |
US10/744,114 Abandoned US20040138125A1 (en) | 2001-09-24 | 2003-12-23 | Composition and method to prevent and treat brain and spinal cord injuries |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/962,009 Expired - Fee Related US6683066B2 (en) | 2001-09-24 | 2001-09-24 | Composition and treatment method for brain and spinal cord injuries |
US10/703,320 Abandoned US20040142905A1 (en) | 2001-09-24 | 2003-11-07 | Compositions and treatment method for brain and spinal cord injuries |
US10/703,830 Abandoned US20040142906A1 (en) | 2001-09-24 | 2003-11-07 | Conpositions and method to prevent and treat brain and spinal cord injuries |
Country Status (3)
Country | Link |
---|---|
US (4) | US6683066B2 (en) |
AU (1) | AU2002335736A1 (en) |
WO (1) | WO2003026565A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034946A1 (en) * | 2004-08-13 | 2006-02-16 | Yanming Wang | Irrigating solution for neurosurgical procedures |
US20060057065A1 (en) * | 2004-09-11 | 2006-03-16 | Yanming Wang | Composition and method to prevent and treat brain and spinal cord injuries |
WO2006125930A1 (en) * | 2005-05-27 | 2006-11-30 | Gemac | Composition for the treatment of multiple sclerosis |
US20070275896A1 (en) * | 2006-05-19 | 2007-11-29 | Neuroprotection, Inc. | Use of Polypeptides in Treating Tissue Injury |
US20100305492A1 (en) * | 2006-10-09 | 2010-12-02 | Shivanand Lad | Cerebrospinal Fluid Purification System |
EP2392342A1 (en) * | 2010-06-04 | 2011-12-07 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Compositions for use in the treatment or diagnosis of prion diseases |
CN106727769A (en) * | 2017-03-01 | 2017-05-31 | 周博成 | The application of one ball plane tree bark extract and preparation method and field of medicaments |
US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
US11577060B2 (en) | 2015-12-04 | 2023-02-14 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040045560A1 (en) * | 2002-05-23 | 2004-03-11 | New England Medical Center Hospitals, Inc. | Computer-assisted multi-dimensional patient-selection |
BR0311702A (en) * | 2002-06-03 | 2005-03-08 | Uab Research Foundation | Use of a clot reducing agent and commercial kit to reduce obstructive hydrocephalus |
US7923032B2 (en) * | 2002-11-26 | 2011-04-12 | Seacoast Neuroscience, Inc. | Buoyant polymer particles for delivery of therapeutic agents to the central nervous system |
JP2009502247A (en) * | 2005-07-21 | 2009-01-29 | ザ クリーブランド クリニック ファウンデーション | Medical vibration compliance device and use thereof |
US7473684B2 (en) * | 2005-09-16 | 2009-01-06 | Selamine Limited | Bisphosphonate formulation |
WO2007139771A1 (en) * | 2006-05-22 | 2007-12-06 | The Johns Hopkins University | Kv channels in neurodegeneration and neuroprotection |
US20080045611A1 (en) * | 2006-08-17 | 2008-02-21 | Milan Radojicic | Methods for the therapeutic use of a carbonic anhydrase inhibitor for reducing spinal cord edema |
GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
US9386939B1 (en) | 2007-05-10 | 2016-07-12 | Fonar Corporation | Magnetic resonance imaging of the spine to detect scoliosis |
WO2009058353A1 (en) * | 2007-11-02 | 2009-05-07 | The Cleveland Clinic Foundation | Device for increasing cerebral blood flow |
US20090123373A1 (en) * | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
WO2011111070A2 (en) * | 2010-03-09 | 2011-09-15 | Bdr Pharmaceuticals International Pvt. Ltd. | Novel injectable combination |
US9649047B1 (en) * | 2011-04-22 | 2017-05-16 | Fonar Corporation | Monitoring and treatment of multiple sclerosis |
US11141080B1 (en) | 2013-03-13 | 2021-10-12 | Fonar Corporation | Cervical vertebra angle measurement |
WO2016077457A1 (en) | 2014-11-11 | 2016-05-19 | Clara Foods Co. | Methods and compositions for egg white protein production |
RU2636616C1 (en) * | 2017-01-17 | 2017-11-24 | Общество С Ограниченной Ответственностью "Научно-Производственное Объединение "Фарматрон" | Combined drug for primary neuroprotection |
WO2020041905A1 (en) * | 2018-08-31 | 2020-03-05 | The University Of British Columbia | Methods for identifying compounds suitable for treatment of central nervous system trauma and uses of those compounds |
KR20220034848A (en) | 2019-07-11 | 2022-03-18 | 클라라 푸드즈 컴퍼니 | Protein composition and edible products thereof |
US10927360B1 (en) | 2019-08-07 | 2021-02-23 | Clara Foods Co. | Compositions comprising digestive enzymes |
CN114099721B (en) * | 2021-11-30 | 2023-07-14 | 华兰生物工程重庆有限公司 | Globulin pasteurization process using combined protectant |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54117034A (en) | 1978-02-28 | 1979-09-11 | Nippon Shoji Kk | Treating agent for consciousness and perception motion disorder |
US4758431A (en) | 1980-04-14 | 1988-07-19 | Thomas Jefferson University | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4393863A (en) | 1980-04-14 | 1983-07-19 | Thomas Jefferson University | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US5085630A (en) | 1980-04-14 | 1992-02-04 | Thomas Jefferson University | Oxygenated fluorocarbon nutrient solution |
US4445500A (en) | 1982-03-03 | 1984-05-01 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4830849A (en) | 1980-04-14 | 1989-05-16 | Thomas Jefferson University | Extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
US4465850A (en) | 1980-09-02 | 1984-08-14 | Merck & Co., Inc. | Treatment of brain injury due to gray matter edema with (indanyloxy) butanoic acids |
US4445887A (en) | 1982-03-03 | 1984-05-01 | Thomas Jefferson University | Stroke treatment utilizing extravascular circulation of oxygenated synthetic nutrients to treat tissue hypoxic and ischemic disorders |
IT1176916B (en) * | 1984-10-10 | 1987-08-18 | Elvira Pistolesi | PHARMACEUTICAL OR DIETETIC COMPOSITION WITH HIGH ANTI-THROMBOTIC AND ANTI-ARTERIOSCLEROTIC ACTIVITY |
US4906644A (en) | 1986-11-20 | 1990-03-06 | Mitsubishi Kasei Corporation | Lipid-peroxide formation inhibiting composition and novel compounds useful therefor |
US5128354A (en) | 1987-12-29 | 1992-07-07 | Dainippon Pharmaceutical Co., Ltd. | Agent for treating ischemic brain damage |
JPH02102290A (en) * | 1988-10-07 | 1990-04-13 | Nippon Oil & Fats Co Ltd | Solubilized tocopherol |
US5395314A (en) | 1990-10-10 | 1995-03-07 | Life Resuscitation Technologies, Inc. | Brain resuscitation and organ preservation device and method for performing the same |
US5486530A (en) | 1991-04-27 | 1996-01-23 | Boehringer Mannheim Gmbh | Use of torasemide for the treatment of brain oedemas |
US5308832A (en) | 1992-07-27 | 1994-05-03 | Abbott Laboratories | Nutritional product for persons having a neurological injury |
US5879677A (en) | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
US5755237A (en) | 1995-06-07 | 1998-05-26 | Rodriguez; Victorio C. | Therapeutic use of acetazolamide for the treatment of brain edema |
WO1999002139A1 (en) | 1997-07-10 | 1999-01-21 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
-
2001
- 2001-09-24 US US09/962,009 patent/US6683066B2/en not_active Expired - Fee Related
-
2002
- 2002-09-11 WO PCT/US2002/028918 patent/WO2003026565A2/en active Search and Examination
- 2002-09-11 AU AU2002335736A patent/AU2002335736A1/en not_active Abandoned
-
2003
- 2003-11-07 US US10/703,320 patent/US20040142905A1/en not_active Abandoned
- 2003-11-07 US US10/703,830 patent/US20040142906A1/en not_active Abandoned
- 2003-12-23 US US10/744,114 patent/US20040138125A1/en not_active Abandoned
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060034946A1 (en) * | 2004-08-13 | 2006-02-16 | Yanming Wang | Irrigating solution for neurosurgical procedures |
US20060057065A1 (en) * | 2004-09-11 | 2006-03-16 | Yanming Wang | Composition and method to prevent and treat brain and spinal cord injuries |
US20060057067A1 (en) * | 2004-09-11 | 2006-03-16 | Yanming Wang | Lymph-like composition and method to prevent and treat central nervous system injuries |
WO2006125930A1 (en) * | 2005-05-27 | 2006-11-30 | Gemac | Composition for the treatment of multiple sclerosis |
FR2886153A1 (en) * | 2005-05-27 | 2006-12-01 | Gemac Sa | COMPOSITION FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
US20090325856A1 (en) * | 2005-05-27 | 2009-12-31 | Gemac | Composition Designed For The Treatment Of Multiple Sclerosis |
US20070275896A1 (en) * | 2006-05-19 | 2007-11-29 | Neuroprotection, Inc. | Use of Polypeptides in Treating Tissue Injury |
US7759309B2 (en) | 2006-05-19 | 2010-07-20 | Yanming Wang | Use of polypeptides in treating tissue injury |
US20200046954A1 (en) | 2006-10-09 | 2020-02-13 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US11065425B2 (en) | 2006-10-09 | 2021-07-20 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US11529452B2 (en) | 2006-10-09 | 2022-12-20 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
US8435204B2 (en) | 2006-10-09 | 2013-05-07 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US10850235B2 (en) | 2006-10-09 | 2020-12-01 | Minnetronix, Inc. | Method for filtering cerebrospinal fluid (CSF) including monitoring CSF flow |
US9895518B2 (en) | 2006-10-09 | 2018-02-20 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US10398884B2 (en) | 2006-10-09 | 2019-09-03 | Neurofluidics, Inc. | Cerebrospinal fluid purification system |
US20100305492A1 (en) * | 2006-10-09 | 2010-12-02 | Shivanand Lad | Cerebrospinal Fluid Purification System |
US10632237B2 (en) | 2006-10-09 | 2020-04-28 | Minnetronix, Inc. | Tangential flow filter system for the filtration of materials from biologic fluids |
EP2392342A1 (en) * | 2010-06-04 | 2011-12-07 | Commissariat à l'Énergie Atomique et aux Énergies Alternatives | Compositions for use in the treatment or diagnosis of prion diseases |
WO2011151798A1 (en) * | 2010-06-04 | 2011-12-08 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Compositions for use in the treatment or diagnosis of prion diseases |
US11147540B2 (en) | 2015-07-01 | 2021-10-19 | Minnetronix, Inc. | Introducer sheath and puncture tool for the introduction and placement of a catheter in tissue |
US11577060B2 (en) | 2015-12-04 | 2023-02-14 | Minnetronix, Inc. | Systems and methods for the conditioning of cerebrospinal fluid |
CN106727769A (en) * | 2017-03-01 | 2017-05-31 | 周博成 | The application of one ball plane tree bark extract and preparation method and field of medicaments |
Also Published As
Publication number | Publication date |
---|---|
US20040142906A1 (en) | 2004-07-22 |
US6683066B2 (en) | 2004-01-27 |
WO2003026565A2 (en) | 2003-04-03 |
WO2003026565A3 (en) | 2003-11-20 |
US20040142905A1 (en) | 2004-07-22 |
US20030059476A1 (en) | 2003-03-27 |
AU2002335736A1 (en) | 2003-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20040138125A1 (en) | Composition and method to prevent and treat brain and spinal cord injuries | |
RU2289424C2 (en) | Using pharmaceutical composition comprising epidermal growth factor (egf) for prevention of diabetic limb amputation | |
ES2728071T3 (en) | Ophthalmological compositions and their use | |
EA003369B1 (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
US20060247293A1 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
US7387798B2 (en) | Method and composition for resuscitation | |
Allen et al. | Intravenous procaine analgesia | |
KR100287991B1 (en) | Ophthalmic Argatroban Formulations | |
Tarter et al. | A clinical study of the use of intravenous urea in glaucoma | |
JPH08503968A (en) | Composition containing growth factor and antimetabolite | |
WO2007072147A2 (en) | Composition for diagnosing and treating circulatory system diseases | |
EP0540747B1 (en) | Medicine for intraocular operation | |
ES2260634T3 (en) | USE OF AN L-ASCORBIC ACID SALT TO PREPARE A PHARMACEUTICAL COMPOSITION FOR OPTICAL TOPICAL USE ABLE TO IMPROVE THE L-ASCORBIC ACID LEVEL OF THE EYE. | |
RU2154421C2 (en) | Method for carrying out artificial controllable lowering of human arterial blood pressure during surgical intervention executed under general anesthesia | |
JP3530542B2 (en) | Argatroban formulation for ophthalmology | |
JPH08325143A (en) | Medicine for curing damage of corneal parenchyma | |
RU2173972C2 (en) | Method for applying anesthesia in ophthalmological operations | |
RU2266737C1 (en) | Method and preparation for treating the cases of hemorrhagic stroke | |
RU2219943C1 (en) | Method for treatment of diabetic retinopathy | |
JP2000083623A (en) | Food | |
SU1438791A1 (en) | Method of treatment of acute nonspecific inflammatory disease of soft tissue of the face and neck | |
KR102244530B1 (en) | Protective solution for preventing or reducing reperfusion injury of the brain and the whole body | |
RU2245141C1 (en) | Method for correcting microcirculatory disorders in patients with thermal trauma | |
CN104116853A (en) | Beautyberry leaf injection with astringency and hemostasis effects and preparation method thereof | |
RU2236234C1 (en) | Homeopathic agent for stabilization of optical function in glaucoma with normalized intraocular pressure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |